{"id":10065,"date":"2020-03-23T14:52:19","date_gmt":"2020-03-23T14:52:19","guid":{"rendered":"https:\/\/www.progeriaresearch.org\/?p=10065"},"modified":"2020-12-14T17:58:16","modified_gmt":"2020-12-14T22:58:16","slug":"application-to-fda-for-lonafarnib-approval-is-done","status":"publish","type":"post","link":"https:\/\/www.progeriaresearch.org\/id\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/","title":{"rendered":"Pengajuan ke FDA untuk persetujuan lonafarnib SUDAH LENGKAP!"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;3.22&#8243;][et_pb_row _builder_version=&#8221;3.25&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;3.25&#8243; custom_padding=&#8221;|||&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text admin_label=&#8221;FDA&#8221; _builder_version=&#8221;4.3.4&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221;]<\/p>\n<p style=\"font-weight: 400;\"><strong><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-10068  alignleft\" src=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA-300x265.jpg\" alt=\"\" width=\"206\" height=\"182\" \/>Application to FDA for lonafarnib approval is COMPLETE!\u00a0\u00a0\u00a0<\/strong><\/p>\n<p style=\"font-weight: 400;\">During an otherwise difficult time for our world, I am happy to share a bright spot: Eiger BioPharmaceuticals has completed submission of a New Drug Application (NDA), seeking approval &#8211; in Europe and the US &#8211; of the drug lonafarnib as a first-ever treatment for Progeria.<\/p>\n<p style=\"font-weight: 400;\">This submission is the culmination of twelve years of research data and four clinical trials, all funded by PRF and made possible by the courageous children and their families, as well as PRF\u2019s wonderful community of donors.<\/p>\n<p style=\"font-weight: 400;\">You can read more about this exciting news\u00a0<a href=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/PRF-Lonafarnib-NDA-Completion-Press-Release-final-PDF-3-23-20.pdf\" target=\"_blank\" rel=\"noopener noreferrer\" data-saferedirecturl=\"https:\/\/www.google.com\/url?q=https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/PRF-Lonafarnib-NDA-Completion-Press-Release-final-PDF-3-23-20.pdf&amp;source=gmail&amp;ust=1585060548571000&amp;usg=AFQjCNE_6Qu8yUr9CDSuYvEVeGJXwXtlYA\">here<\/a>.<\/p>\n<p style=\"font-weight: 400;\">Our hope is that this drug will be approved, enabling these children and young adults to access lonafarnib \u2013 which has been shown to give them stronger hearts and longer lives &#8211; by prescription, instead of through a clinical trial.<\/p>\n<p style=\"font-weight: 400;\">While 2020 has started off as a difficult year for many, we are happy to share a bit of good news with you. All of us at The Progeria Research Foundation have worked tirelessly to make a meaningful impact on the lives of children and young adults with Progeria.<\/p>\n<p style=\"font-weight: 400;\">THANK YOU ALL for supporting the research that not only has brought us to this pivotal point, but also allows us to continue working to discover new drugs that will ultimately cure these extraordinary children.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Di tengah masa sulit yang dialami dunia kita, kami gembira dapat berbagi kabar baik: Eiger BioPharmaceuticals telah menyelesaikan pengajuan Aplikasi Obat Baru (NDA), yang mencari persetujuan \u2013 di Eropa dan AS \u2013 atas obat lonafarnib sebagai pengobatan pertama untuk Progeria.<\/p>","protected":false},"author":2,"featured_media":10068,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[2],"tags":[],"class_list":["post-10065","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Application to FDA for lonafarnib approval is COMPLETE! - The Progeria Research Foundation<\/title>\n<meta name=\"description\" content=\"During an otherwise difficult time for our world, we are happy to share a bright spot: Eiger BioPharmaceuticals has completed submission of a New Drug Application (NDA), seeking approval - in Europe and the US - of the drug lonafarnib as a first-ever treatment for Progeria.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.progeriaresearch.org\/id\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/\" \/>\n<meta property=\"og:locale\" content=\"id_ID\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Application to FDA for lonafarnib approval is COMPLETE! - The Progeria Research Foundation\" \/>\n<meta property=\"og:description\" content=\"During an otherwise difficult time for our world, we are happy to share a bright spot: Eiger BioPharmaceuticals has completed submission of a New Drug Application (NDA), seeking approval - in Europe and the US - of the drug lonafarnib as a first-ever treatment for Progeria.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.progeriaresearch.org\/id\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/\" \/>\n<meta property=\"og:site_name\" content=\"The Progeria Research Foundation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ProgeriaResearch\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-03-23T14:52:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-12-14T22:58:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"529\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Karen Betournay\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Progeria\" \/>\n<meta name=\"twitter:site\" content=\"@Progeria\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Karen Betournay\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 menit\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/hi\\\/2020\\\/03\\\/23\\\/application-to-fda-for-lonafarnib-approval-is-done\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/hi\\\/2020\\\/03\\\/23\\\/application-to-fda-for-lonafarnib-approval-is-done\\\/\"},\"author\":{\"name\":\"Karen Betournay\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#\\\/schema\\\/person\\\/2be6cec85c11aaef7a7602636c5b9946\"},\"headline\":\"Application to FDA for lonafarnib approval is COMPLETE!\",\"datePublished\":\"2020-03-23T14:52:19+00:00\",\"dateModified\":\"2020-12-14T22:58:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/hi\\\/2020\\\/03\\\/23\\\/application-to-fda-for-lonafarnib-approval-is-done\\\/\"},\"wordCount\":294,\"publisher\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/hi\\\/2020\\\/03\\\/23\\\/application-to-fda-for-lonafarnib-approval-is-done\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.progeriaresearch.org\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/FDA.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"id\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/hi\\\/2020\\\/03\\\/23\\\/application-to-fda-for-lonafarnib-approval-is-done\\\/\",\"url\":\"https:\\\/\\\/www.progeriaresearch.org\\\/hi\\\/2020\\\/03\\\/23\\\/application-to-fda-for-lonafarnib-approval-is-done\\\/\",\"name\":\"Application to FDA for lonafarnib approval is COMPLETE! - The Progeria Research Foundation\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/hi\\\/2020\\\/03\\\/23\\\/application-to-fda-for-lonafarnib-approval-is-done\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/hi\\\/2020\\\/03\\\/23\\\/application-to-fda-for-lonafarnib-approval-is-done\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.progeriaresearch.org\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/FDA.jpg\",\"datePublished\":\"2020-03-23T14:52:19+00:00\",\"dateModified\":\"2020-12-14T22:58:16+00:00\",\"description\":\"During an otherwise difficult time for our world, we are happy to share a bright spot: Eiger BioPharmaceuticals has completed submission of a New Drug Application (NDA), seeking approval - in Europe and the US - of the drug lonafarnib as a first-ever treatment for Progeria.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/hi\\\/2020\\\/03\\\/23\\\/application-to-fda-for-lonafarnib-approval-is-done\\\/#breadcrumb\"},\"inLanguage\":\"id\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.progeriaresearch.org\\\/hi\\\/2020\\\/03\\\/23\\\/application-to-fda-for-lonafarnib-approval-is-done\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"id\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/hi\\\/2020\\\/03\\\/23\\\/application-to-fda-for-lonafarnib-approval-is-done\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.progeriaresearch.org\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/FDA.jpg\",\"contentUrl\":\"https:\\\/\\\/www.progeriaresearch.org\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/FDA.jpg\",\"width\":600,\"height\":529},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/hi\\\/2020\\\/03\\\/23\\\/application-to-fda-for-lonafarnib-approval-is-done\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.progeriaresearch.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Application to FDA for lonafarnib approval is COMPLETE!\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#website\",\"url\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/\",\"name\":\"The Progeria Research Foundation\",\"description\":\"For the Children \u2665 For the Cure\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"id\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#organization\",\"name\":\"The Progeria Research Foundation\",\"url\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"id\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.progeriaresearch.org\\\/wp-content\\\/uploads\\\/2019\\\/05\\\/PRF_Logo_2019_optimized.png\",\"contentUrl\":\"https:\\\/\\\/www.progeriaresearch.org\\\/wp-content\\\/uploads\\\/2019\\\/05\\\/PRF_Logo_2019_optimized.png\",\"width\":300,\"height\":86,\"caption\":\"The Progeria Research Foundation\"},\"image\":{\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ProgeriaResearch\\\/\",\"https:\\\/\\\/x.com\\\/Progeria\",\"https:\\\/\\\/www.instagram.com\\\/progeriaresearch\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.progeriaresearch.org\\\/ta\\\/#\\\/schema\\\/person\\\/2be6cec85c11aaef7a7602636c5b9946\",\"name\":\"Karen Betournay\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"id\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"caption\":\"Karen Betournay\"},\"url\":\"https:\\\/\\\/www.progeriaresearch.org\\\/id\\\/author\\\/karenb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pengajuan permohonan persetujuan lonafarnib ke FDA telah SELESAI! - Yayasan Penelitian Progeria","description":"Di tengah masa-masa sulit bagi dunia kita, kami dengan senang hati berbagi kabar gembira: Eiger BioPharmaceuticals telah menyelesaikan pengajuan Permohonan Obat Baru (NDA), yang bertujuan untuk mendapatkan persetujuan - di Eropa dan AS - untuk obat lonafarnib sebagai pengobatan pertama untuk Progeria.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.progeriaresearch.org\/id\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/","og_locale":"id_ID","og_type":"article","og_title":"Application to FDA for lonafarnib approval is COMPLETE! - The Progeria Research Foundation","og_description":"During an otherwise difficult time for our world, we are happy to share a bright spot: Eiger BioPharmaceuticals has completed submission of a New Drug Application (NDA), seeking approval - in Europe and the US - of the drug lonafarnib as a first-ever treatment for Progeria.","og_url":"https:\/\/www.progeriaresearch.org\/id\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/","og_site_name":"The Progeria Research Foundation","article_publisher":"https:\/\/www.facebook.com\/ProgeriaResearch\/","article_published_time":"2020-03-23T14:52:19+00:00","article_modified_time":"2020-12-14T22:58:16+00:00","og_image":[{"width":600,"height":529,"url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg","type":"image\/jpeg"}],"author":"Karen Betournay","twitter_card":"summary_large_image","twitter_creator":"@Progeria","twitter_site":"@Progeria","twitter_misc":{"Written by":"Karen Betournay","Est. reading time":"1 menit"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#article","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/"},"author":{"name":"Karen Betournay","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946"},"headline":"Application to FDA for lonafarnib approval is COMPLETE!","datePublished":"2020-03-23T14:52:19+00:00","dateModified":"2020-12-14T22:58:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/"},"wordCount":294,"publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg","articleSection":["News"],"inLanguage":"id"},{"@type":"WebPage","@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/","url":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/","name":"Pengajuan permohonan persetujuan lonafarnib ke FDA telah SELESAI! - Yayasan Penelitian Progeria","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#primaryimage"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg","datePublished":"2020-03-23T14:52:19+00:00","dateModified":"2020-12-14T22:58:16+00:00","description":"Di tengah masa-masa sulit bagi dunia kita, kami dengan senang hati berbagi kabar gembira: Eiger BioPharmaceuticals telah menyelesaikan pengajuan Permohonan Obat Baru (NDA), yang bertujuan untuk mendapatkan persetujuan - di Eropa dan AS - untuk obat lonafarnib sebagai pengobatan pertama untuk Progeria.","breadcrumb":{"@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#breadcrumb"},"inLanguage":"id","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/"]}]},{"@type":"ImageObject","inLanguage":"id","@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#primaryimage","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2020\/03\/FDA.jpg","width":600,"height":529},{"@type":"BreadcrumbList","@id":"https:\/\/www.progeriaresearch.org\/hi\/2020\/03\/23\/application-to-fda-for-lonafarnib-approval-is-done\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.progeriaresearch.org\/"},{"@type":"ListItem","position":2,"name":"Application to FDA for lonafarnib approval is COMPLETE!"}]},{"@type":"WebSite","@id":"https:\/\/www.progeriaresearch.org\/ta\/#website","url":"https:\/\/www.progeriaresearch.org\/ta\/","name":"Yayasan Penelitian Progeria","description":"Untuk Anak-anak \u2665 Untuk Penyembuhan","publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"id"},{"@type":"Organization","@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization","name":"Yayasan Penelitian Progeria","url":"https:\/\/www.progeriaresearch.org\/ta\/","logo":{"@type":"ImageObject","inLanguage":"id","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","width":300,"height":86,"caption":"The Progeria Research Foundation"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ProgeriaResearch\/","https:\/\/x.com\/Progeria","https:\/\/www.instagram.com\/progeriaresearch\/"]},{"@type":"Person","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946","name":"Karen Betournay","image":{"@type":"ImageObject","inLanguage":"id","@id":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","caption":"Karen Betournay"},"url":"https:\/\/www.progeriaresearch.org\/id\/author\/karenb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.progeriaresearch.org\/id\/wp-json\/wp\/v2\/posts\/10065","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.progeriaresearch.org\/id\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.progeriaresearch.org\/id\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/id\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/id\/wp-json\/wp\/v2\/comments?post=10065"}],"version-history":[{"count":0,"href":"https:\/\/www.progeriaresearch.org\/id\/wp-json\/wp\/v2\/posts\/10065\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/id\/wp-json\/wp\/v2\/media\/10068"}],"wp:attachment":[{"href":"https:\/\/www.progeriaresearch.org\/id\/wp-json\/wp\/v2\/media?parent=10065"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/id\/wp-json\/wp\/v2\/categories?post=10065"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/id\/wp-json\/wp\/v2\/tags?post=10065"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}